Page last updated: 2024-11-04
temozolomide and Cells, Neoplasm Circulating
temozolomide has been researched along with Cells, Neoplasm Circulating in 2 studies
Research Excerpts
| Excerpt | Relevance | Reference |
|---|
| "Differentiating treatment necrosis from tumor recurrence poses a diagnostic conundrum for many clinicians in neuro-oncology." | 1.62 | Role of circulating tumor cell detection in differentiating tumor recurrence from treatment necrosis of brain gliomas. ( Cui, Y; Gao, F; Jiang, H; Li, M; Lin, S; Ren, X; Zhao, W, 2021) |
Research
Studies (2)
| Timeframe | Studies, this research(%) | All Research% |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
Authors
| Authors | Studies |
|---|
| Gao, F | 1 |
| Zhao, W | 1 |
| Li, M | 1 |
| Ren, X | 1 |
| Jiang, H | 1 |
| Cui, Y | 1 |
| Lin, S | 1 |
| Pietanza, MC | 1 |
| Waqar, SN | 1 |
| Krug, LM | 1 |
| Dowlati, A | 1 |
| Hann, CL | 1 |
| Chiappori, A | 1 |
| Owonikoko, TK | 1 |
| Woo, KM | 1 |
| Cardnell, RJ | 1 |
| Fujimoto, J | 1 |
| Long, L | 1 |
| Diao, L | 1 |
| Wang, J | 1 |
| Bensman, Y | 1 |
| Hurtado, B | 1 |
| de Groot, P | 1 |
| Sulman, EP | 1 |
| Wistuba, II | 1 |
| Chen, A | 1 |
| Fleisher, M | 1 |
| Heymach, JV | 1 |
| Kris, MG | 1 |
| Rudin, CM | 1 |
| Byers, LA | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status |
|---|
| A Multi-Center, Randomized, Double-Blind Phase II Study Comparing ABT-888, a PARP Inhibitor, Versus Placebo With Temozolomide in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer[NCT01638546] | Phase 2 | 97 participants (Actual) | Interventional | 2012-06-30 | Completed |
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
Number of Participants With Adverse Events
Tabulated According to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0. Summary level. (NCT01638546)
Timeframe: From the start of treatment until 30 days from coming off treatment
| Intervention | Participants (Count of Participants) |
|---|
| Arm I (Veliparib and Temozolomide) | 52 |
| Arm II (Placebo and Temozolomide) | 45 |
Overall Response (ORR) by RECIST 1.1 Criteria
Corresponding exact two-sided 95% confidence intervals will be calculated and reported in both arms of the study. Comparisons between treatment arms will be performed using Fisher-exact test. (NCT01638546)
Timeframe: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 4 months
| Intervention | participants (Number) |
|---|
| Arm I (Veliparib and Temozolomide) | 20 |
| Arm II (Placebo and Temozolomide) | 6 |
Overall Survival
Estimated in each treatment group using Kaplan-Meier method. Group comparisons will be performed using log-rank test. (NCT01638546)
Timeframe: From randomization to time of death
| Intervention | months (Median) |
|---|
| Arm I (Veliparib and Temozolomide) | 8.2 |
| Arm II (Placebo and Temozolomide) | 7 |
Progression-free Survival, Calculated as the Proportion of Patients Alive and Without Evidence of Disease
Compared across the two arms using a Fisher exact test. (NCT01638546)
Timeframe: From randomization to time of progression or death, whichever occurs first, assessed at 4 months
| Intervention | participants (Number) |
|---|
| Arm I (Veliparib and Temozolomide) | 18 |
| Arm II (Placebo and Temozolomide) | 11 |
Trials
1 trial available for temozolomide and Cells, Neoplasm Circulating
Other Studies
1 other study available for temozolomide and Cells, Neoplasm Circulating